Compare BHE & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHE | AGIO |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1996 | 2013 |
| Metric | BHE | AGIO |
|---|---|---|
| Price | $83.20 | $28.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $55.00 | $38.88 |
| AVG Volume (30 Days) | 435.7K | ★ 1.2M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $2,659,108,000.00 | $43,011,000.00 |
| Revenue This Year | $7.03 | $76.75 |
| Revenue Next Year | $6.57 | $170.73 |
| P/E Ratio | $230.65 | ★ N/A |
| Revenue Growth | ★ 0.11 | N/A |
| 52 Week Low | $34.44 | $22.24 |
| 52 Week High | $87.73 | $46.00 |
| Indicator | BHE | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.09 | 49.56 |
| Support Level | $39.25 | $26.42 |
| Resistance Level | $87.73 | $29.39 |
| Average True Range (ATR) | 3.92 | 0.87 |
| MACD | -0.69 | 0.22 |
| Stochastic Oscillator | 62.15 | 73.03 |
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.